Novartis has announced that phase 3 clinical trials data published in the Lancet showed significant benefit of its cancer drug, Afinitor (everolimus) in patients with non-cancerous tumours ...

In final draft guidance, NICE said an updated cost-effectiveness analysis had convinced it that Novartis' Afinitor (everolimus) daily pill in combination with exemestane (Pfizer's off-patent ...

Novartis AG (NOVN.VX) said on Friday its Afinitor drug failed to make a significant difference in disease-free survival of patients with a type of advanced breast cancer that affects about a fifth ...

The COMPETE trial evaluated ITM-11 in direct comparison with Afinitor in 309 patients with ... 177Lu-edotreotide becomes the first drug candidate in ITM’s broad portfolio of early-to late ...